Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple Sclerosis
Neurol Ther. 2024 Apr 8. doi: 10.1007/s40120-024-00603-y. Online ahead of print.ABSTRACTThe number of ageing people with relapsing multiple sclerosis (RMS) is increasing. The efficacy of disease-modifying therapies (DMTs) for RMS declines with age. Also, older persons with MS may be more susceptible to infections, hospitalisations and malignancy. Aging people with MS have higher rates of comorbidities versus aged-matched controls, increasing the individual risk of disability. We review the therapeutic properties of cladribine tablets (CladT) in ageing people with RMS, with regard to their utility for allowing these individ...
Source: Herpes - April 8, 2024 Category: Infectious Diseases Authors: Jerome de Seze Dominique Dive Xavier Ayrignac Giovanni Castelnovo Marianne Payet Amel Rayah Claudio Gobbi Patrick Vermersch Chiara Zecca Source Type: research
Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple Sclerosis
AbstractThe number of ageing people with relapsing multiple sclerosis (RMS) is increasing. The efficacy of disease-modifying therapies (DMTs) for RMS declines with age. Also, older persons with MS may be more susceptible to infections, hospitalisations and malignancy. Aging people with MS have higher rates of comorbidities versus aged-matched controls, increasing the individual risk of disability. We review the therapeutic properties of cladribine tablets (CladT) in ageing people with RMS, with regard to their utility for allowing these individuals to cease continuous administration of a DMT (i.e. to act as an “exit ther...
Source: Neurology and Therapy - April 8, 2024 Category: Neurology Source Type: research
Prior pneumococcal vaccination improves in-hospital mortality among elderly population hospitalized due to community-acquired pneumonia
Pneumococcal vaccination is a preventive method to reduce pneumonia related mortality. However, real-world data on efficacy of the pneumococcal vaccine in reducing mortality is lacking, especially in elderly p... (Source: BMC Pulmonary Medicine)
Source: BMC Pulmonary Medicine - April 8, 2024 Category: Respiratory Medicine Authors: Seohyun Kim, Moon Jin Kim, Jun-Pyo Myong, Yun-Hee Lee, Bo Yeon Kim, Ahyoung Hwang, Gui Ok Kim, Sung Hwan Jeong, Hyoung Kyu Yoon, Tai Joon An and Jeong Uk Lim Tags: Research Source Type: research
Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13
CONCLUSIONS: Changes in uptake of PCV13 and PPV23 among those aged 70 + years were consistent with program changes. However, PCV13 uptake was still substantially lower in individuals aged 65-69 years overall and in those with comorbidities.PMID:38584056 | DOI:10.1016/j.vaccine.2024.04.012 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Fariha Binte Hossain David Muscatello Sanjay Jayasinghe Jitendra Jonnagaddala Bette Liu Source Type: research
Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13
CONCLUSIONS: Changes in uptake of PCV13 and PPV23 among those aged 70 + years were consistent with program changes. However, PCV13 uptake was still substantially lower in individuals aged 65-69 years overall and in those with comorbidities.PMID:38584056 | DOI:10.1016/j.vaccine.2024.04.012 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Fariha Binte Hossain David Muscatello Sanjay Jayasinghe Jitendra Jonnagaddala Bette Liu Source Type: research
Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13
CONCLUSIONS: Changes in uptake of PCV13 and PPV23 among those aged 70 + years were consistent with program changes. However, PCV13 uptake was still substantially lower in individuals aged 65-69 years overall and in those with comorbidities.PMID:38584056 | DOI:10.1016/j.vaccine.2024.04.012 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Fariha Binte Hossain David Muscatello Sanjay Jayasinghe Jitendra Jonnagaddala Bette Liu Source Type: research
Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13
CONCLUSIONS: A PCV20 catch-up program could prevent pneumococcal infections, antibiotic prescriptions and antimicrobial-resistant infections and would be cost saving in the US.PMID:38577742 | DOI:10.1080/13696998.2024.2339638 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 5, 2024 Category: Health Management Authors: Mark H Rozenbaum Liping Huang Alejandro Cane Adriano Arguedas Ruth Chapman Desmond Dillon-Murphy Maria Tort Vincenza Snow Erica Chilson Raymond Farkouh Source Type: research
Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older
This study assesses the cost-effectiveness of PCV21 in US adults aged 50 years or older compared with currently recommended pneumococcal vaccines, from both the societal and healthcare perspectives. A Markov model evaluated the lifetime cost-effectiveness of PCV21 (given at age 50 years only, at ages 50/65 years, and risk-based at ages < 65 years plus age-based at age 65 years) compared to no vaccination and to currently recommended pneumococcal vaccines given either as currently recommended or routinely at ages 50/65 years. The analysis was conducted in hypothetical Black and non-Black cohorts aged 50 years or older, w...
Source: Vaccine - April 5, 2024 Category: Allergy & Immunology Authors: Shoroq M Altawalbeh Angela R Wateska Mary Patricia Nowalk Chyongchiou J Lin Lee H Harrison William Schaffner Richard K Zimmerman Kenneth J Smith Source Type: research
Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13
CONCLUSIONS: A PCV20 catch-up program could prevent pneumococcal infections, antibiotic prescriptions and antimicrobial-resistant infections and would be cost saving in the US.PMID:38577742 | DOI:10.1080/13696998.2024.2339638 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 5, 2024 Category: Health Management Authors: Mark H Rozenbaum Liping Huang Alejandro Cane Adriano Arguedas Ruth Chapman Desmond Dillon-Murphy Maria Tort Vincenza Snow Erica Chilson Raymond Farkouh Source Type: research
Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older
This study assesses the cost-effectiveness of PCV21 in US adults aged 50 years or older compared with currently recommended pneumococcal vaccines, from both the societal and healthcare perspectives. A Markov model evaluated the lifetime cost-effectiveness of PCV21 (given at age 50 years only, at ages 50/65 years, and risk-based at ages < 65 years plus age-based at age 65 years) compared to no vaccination and to currently recommended pneumococcal vaccines given either as currently recommended or routinely at ages 50/65 years. The analysis was conducted in hypothetical Black and non-Black cohorts aged 50 years or older, w...
Source: Vaccine - April 5, 2024 Category: Allergy & Immunology Authors: Shoroq M Altawalbeh Angela R Wateska Mary Patricia Nowalk Chyongchiou J Lin Lee H Harrison William Schaffner Richard K Zimmerman Kenneth J Smith Source Type: research
Retrospective study on the health and economic burden of hospitalized patients due to pneumonia and invasive pneumococcal infections in Belgium settings
CONCLUSION: Streptococcus pneumoniae infections remain a public health problem with significant cost for the Health Insurance and poor prognosis. Invasive pneumococcal infections are associated with longer hospital stays and required more intensive care than all other causes of pneumonia, in addition to be more costly, which justifies more attention for vaccination. This study also suggests an increase of economic and health burden with age and presence of underlying conditions.PMID:38575434 | DOI:10.1016/j.vaccine.2024.03.057 (Source: Vaccine)
Source: Vaccine - April 4, 2024 Category: Allergy & Immunology Authors: Pirson Magali Marbaix Sophie Bruyneel Arnaud Leclercq Pol Van Den Bulcke Julie Brauner Jonathan Source Type: research
Retrospective study on the health and economic burden of hospitalized patients due to pneumonia and invasive pneumococcal infections in Belgium settings
CONCLUSION: Streptococcus pneumoniae infections remain a public health problem with significant cost for the Health Insurance and poor prognosis. Invasive pneumococcal infections are associated with longer hospital stays and required more intensive care than all other causes of pneumonia, in addition to be more costly, which justifies more attention for vaccination. This study also suggests an increase of economic and health burden with age and presence of underlying conditions.PMID:38575434 | DOI:10.1016/j.vaccine.2024.03.057 (Source: Vaccine)
Source: Vaccine - April 4, 2024 Category: Allergy & Immunology Authors: Pirson Magali Marbaix Sophie Bruyneel Arnaud Leclercq Pol Van Den Bulcke Julie Brauner Jonathan Source Type: research
Novel method for production and purification of untagged pneumococcal surface protein A from clade 1
Appl Microbiol Biotechnol. 2024 Apr 4;108(1):281. doi: 10.1007/s00253-024-13098-2.ABSTRACTStreptococcus pneumoniae can cause diseases with high mortality and morbidity. The licensed vaccines are based on capsular polysaccharides and induce antibodies with low cross reactivity, leading to restricted coverage of serotypes. For surpassing this limitation, new pneumococcal vaccines are needed for induction of broader protection. One important candidate is the pneumococcal surface protein A (PspA), which can be classified in 6 clades and 3 families. We have reported an efficient process for production and purification of untagg...
Source: Applied Microbiology and Biotechnology - April 3, 2024 Category: Microbiology Authors: Tasson da Costa Rodrigues Patricia Zorzete Eliane Namie Miyaji Viviane Maimoni Gon çalves Source Type: research
Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation
CONCLUSION: This study demonstrates that despite high PCV13 efficacy against experimental Spn6B carriage in young, healthy Malawian adults, robust vaccine-induced systemic and mucosal anti-Spn6B CPS binding antibodies did not directly relate to protection.PMID:38570270 | DOI:10.1016/j.vaccine.2024.03.055 (Source: Vaccine)
Source: Vaccine - April 3, 2024 Category: Allergy & Immunology Authors: G Tembo M Mayuni R Kamng'ona L Chimgoneko G Chiwala S Sichone B Galafa F Thole C Mkandawire A E Chirwa E Nsomba V Nkhoma C Ngoliwa N Toto L Makhaza A Muyaya E Kudowa M Y R Henrion D Dula B Morton T Chikaonda S B Gordon K C Jambo Source Type: research
State of pneumococcal vaccine immunity
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - April 3, 2024 Category: Allergy & Immunology Authors: Mustafa AkkoyunluDivision of Bacterial Allergenic and Parasitic Diseases, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA Source Type: research
